Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis

Abstract

This study provides Class II evidence that patients with POMS treated with natalizumab had a lower risk of relapse than those with fingolimod.